These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29563490)

  • 1. miR-451a abrogates treatment resistance in FLT3-ITD-positive acute myeloid leukemia.
    Krakowsky RHE; Wurm AA; Gerloff D; Katzerke C; Bräuer-Hartmann D; Hartmann JU; Wilke F; Thiede C; Müller-Tidow C; Niederwieser D; Behre G
    Blood Cancer J; 2018 Mar; 8(3):36. PubMed ID: 29563490
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.
    Khalife J; Radomska HS; Santhanam R; Huang X; Neviani P; Saultz J; Wang H; Wu YZ; Alachkar H; Anghelina M; Dorrance A; Curfman J; Bloomfield CD; Medeiros BC; Perrotti D; Lee LJ; Lee RJ; Caligiuri MA; Pichiorri F; Croce CM; Garzon R; Guzman ML; Mendler JH; Marcucci G
    Leukemia; 2015 Oct; 29(10):1981-92. PubMed ID: 25971362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
    Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations.
    Scholl S; Spies-Weisshart B; Klink A; Muegge LO; Fricke HJ; Hochhaus A
    Ann Hematol; 2011 Apr; 90(4):473-5. PubMed ID: 20652568
    [No Abstract]   [Full Text] [Related]  

  • 5. FLT3-ITD drives Ara-C resistance in leukemic cells via the induction of RUNX3.
    Damdinsuren A; Matsushita H; Ito M; Tanaka M; Jin G; Tsukamoto H; Asai S; Ando K; Miyachi H
    Leuk Res; 2015 Dec; 39(12):1405-13. PubMed ID: 26475207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.
    Al-Jamal HA; Mat Jusoh SA; Hassan R; Johan MF
    BMC Cancer; 2015 Nov; 15():869. PubMed ID: 26547689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors.
    Habif G; Grasset MF; Kieffer-Jaquinod S; Kuhn L; Mouchiroud G; Gobert-Gosse S
    J Proteomics; 2013 Jan; 78():231-44. PubMed ID: 23017497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.
    Albers C; Leischner H; Verbeek M; Yu C; Illert AL; Peschel C; von Bubnoff N; Duyster J
    Leukemia; 2013 Jun; 27(6):1416-8. PubMed ID: 23392356
    [No Abstract]   [Full Text] [Related]  

  • 9. [Expression of FLT3 internal tandem duplication in pediatric patients with acute myeloid leukemia and its correlation with multidrug resistance].
    Zhao JN; Qiao ZH; Xu LR; Lu QY; Niu XQ; Zhang P; Wang Z
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):23-6. PubMed ID: 19236740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-155 regulative network in FLT3 mutated acute myeloid leukemia.
    Salemi D; Cammarata G; Agueli C; Augugliaro L; Corrado C; Bica MG; Raimondo S; Marfia A; Randazzo V; Dragotto P; Di Raimondo F; Alessandro R; Fabbiano F; Santoro A
    Leuk Res; 2015 Aug; 39(8):883-96. PubMed ID: 26055960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NFATc1 as a therapeutic target in FLT3-ITD-positive AML.
    Metzelder SK; Michel C; von Bonin M; Rehberger M; Hessmann E; Inselmann S; Solovey M; Wang Y; Sohlbach K; Brendel C; Stiewe T; Charles J; Ten Haaf A; Ellenrieder V; Neubauer A; Gattenlöhner S; Bornhäuser M; Burchert A
    Leukemia; 2015 Jul; 29(7):1470-7. PubMed ID: 25976987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
    Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
    Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.
    Staudt D; Murray HC; McLachlan T; Alvaro F; Enjeti AK; Verrills NM; Dun MD
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30332834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Future of Targeting FLT3 Activation in AML.
    Leick MB; Levis MJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro.
    Heidel F; Lipka DB; Mirea FK; Mahboobi S; Grundler R; Kancha RK; Duyster J; Naumann M; Huber C; Böhmer FD; Fischer T
    Br J Haematol; 2009 Mar; 144(6):865-74. PubMed ID: 19183186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FLT3 Internal Tandem Duplication Mutation, cMPL and CD34 Expressions Predict Low Survival in Acute Myeloid Leukemia Patients.
    Ebrahim EK; Assem MM; Amin AI; Kamel MM; El Meligui YM; Metwally AM
    Ann Clin Lab Sci; 2016 Dec; 46(6):592-600. PubMed ID: 27993871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
    Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
    Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
    Xu B; Zhao Y; Wang X; Gong P; Ge W
    Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples.
    Cloos J; Goemans BF; Hess CJ; van Oostveen JW; Waisfisz Q; Corthals S; de Lange D; Boeckx N; Hählen K; Reinhardt D; Creutzig U; Schuurhuis GJ; Zwaan ChM; Kaspers GJ
    Leukemia; 2006 Jul; 20(7):1217-20. PubMed ID: 16642044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant monitoring of WT1 and FLT3-ITD expression in FLT3-ITD acute myeloid leukemia patients: which should we trust as a minimal residual disease marker?
    De Marchi F; Candoni A; Zannier ME; Haley L; Lau BW; Fanin R
    Am J Hematol; 2017 May; 92(5):E72-E74. PubMed ID: 28211167
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.